EpCAM Biomarker Segmentation for Thyroid Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable biomarkers for identifying aggressive thyroid cancer, particularly anaplastic thyroid cancer, leading to challenges in distinguishing between aggressive and non-aggressive forms, which affects treatment strategies and patient outcomes.
Innovation Solution
The use of EpCAM polypeptides, specifically the ectodomain (EpEx) and intracellular domain (Ep-ICD), along with β-catenin, as biomarkers to detect, diagnose, and monitor thyroid cancer, including aggressive forms, by assessing their presence and expression levels in patient samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods are used for thyroid cancer detection, then the diagnostic process is simple, but the sensitivity and specificity for identifying aggressive thyroid cancer are insufficient
Solution Approach 1:
The patent segments the EpCAM protein into two distinct domains for detection: the extracellular domain (EpEx) and the intracellular domain (Ep-ICD). By using separate antibodies targeting each domain, the method achieves enhanced diagnostic sensitivity and specificity for aggressive thyroid cancer while maintaining a relatively simple diagnostic workflow. The segmentation allows for differential detection patterns that distinguish aggressive from non-aggressive thyroid cancers.
Solution Approach 2:
The patent changes the detection parameter from detecting only the extracellular domain (conventional method) to detecting both extracellular and intracellular domains. This parameter change—specifically targeting nuclear Ep-ICD in addition to membrane EpEx—provides superior sensitivity and specificity for identifying aggressive thyroid cancer, as the nuclear localization of Ep-ICD is a distinctive feature of aggressive forms.
2Measurement precision
If multiple biomarkers are used to improve detection accuracy, then the sensitivity and specificity increase, but the complexity of the diagnostic procedure increases
Solution Approach 1:
Instead of using multiple different biomarkers, the patent segments a single biomarker (EpCAM) into two domains that can be detected by different antibodies. This approach achieves high measurement precision in distinguishing aggressive from non-aggressive thyroid cancer while avoiding the complexity of coordinating multiple independent biomarker assays. The segmented approach uses a unified diagnostic framework with clear interpretive criteria.
Solution Approach 2:
The EpCAM protein serves multiple diagnostic functions within a single unified marker system. By detecting both EpEx and Ep-ICD, the same biomarker provides information about both the presence of thyroid cancer and its aggressive nature. This multi-functionality eliminates the need for separate biomarkers for different diagnostic purposes, simplifying the overall diagnostic procedure while maintaining high accuracy.
3Reliability
If conventional EpCAM detection methods are used, then the methodology is well-established, but the ability to identify aggressive thyroid cancer is limited
Solution Approach 1:
The patent introduces nuclear Ep-ICD detection as an intermediary marker that bridges conventional EpCAM detection and aggressive cancer identification. The intracellular domain serves as a mediator that translates the well-established EpCAM detection platform into a tool for identifying aggressive thyroid cancer. This intermediary approach leverages existing antibody technologies while adding the critical capability to distinguish aggressive from non-aggressive forms.
Solution Approach 2:
The patent performs preliminary identification of aggressive thyroid cancer features through nuclear Ep-ICD detection before final diagnostic classification. By预先 detecting the nuclear localization pattern and combining it with membrane EpEx detection, the method prepares comprehensive diagnostic information that enables accurate identification of aggressive cancer types, facilitating timely and appropriate treatment planning.
Data Source
AI summary
Methods for detecting, diagnosing and monitoring thyroid cancer in a subject are described comprising measuring in a sample from the subject markers including Ep-ICD and EpEX. The invention also provides kits and compositions for carrying out the methods of the invention.